Deleuran, M. (2021) “Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use”, Acta Dermato-Venereologica, 101(7), p. adv00504. doi: 10.2340/00015555-3848.